New immunotherapy may help prolong the survival of a common type of brain cancer

The berghofer Institute of medicine in Australia has developed a new cell-based immunotherapy that extends the average survival of patients with glioblastoma multiforme in clinical trials. Related papers have been published in the new issue of the United States. Glioblastoma multiforme is a common and highly malignant tumor in the central nervous system of the brain. It is easy to relapse after treatment. The average survival time of patients after diagnosis is only 14 to 17 months. Berghofer Institute of Medicine recently released a statement saying that Professor Rajiv Connor and his colleagues have developed a new cell-based immunotherapy. In clinical treatment, blood samples are extracted from patients, and human T cells are artificially enhanced before being re injected into patients, so that they can recognize and kill cytomegalovirus. Previous studies have suggested that the pathogenesis of glioblastoma multiforme may be related to cytomegalovirus infection, because of the high expression rate of cytomegalovirus in cancer cells of patients. < / P > < p > in the phase I clinical trial, 25 patients with glioblastoma multiforme who had completed conventional treatment such as surgery received this immunotherapy as adjuvant therapy. The results showed that the average survival time of these patients increased to 21 months, which was higher than that of patients with this type of brain cancer, and the treatment was safe for patients. The researchers said the treatment would be further improved. Focus